TDOC Stock — Teladoc Health, Inc.

Up next

Next earnings call

Oct 29, 2026 Est · unconfirmed · in 9 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Jul 30, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Research

our published analysis of this company

Research Thesis July 19, 2026

Hims & Hers has 26.4% shorts arguing against $2.9B of guided 2026 revenue; the Q2 print decides whether subscriber growth or ARPU decay wins

Hims & Hers closed at $32.84, off 50.4% from its 52-week high, with short interest at 26.4% of shares outstanding and the steepest positioning in the comp set against a +59.0% TTM revenue base and a 10%–12% full-year adjusted EBITDA guide — the next quarter decides whether the multiple re-rates with subscriber growth or compresses further on the 6% ARPU slide.

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Neutral Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 14.5 · calm Equity put/call 0.39

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −5%

below

Price vs 50-day avg −20%

below

RSI (14) 37

neutral

MACD trend Positive

52-week position 36%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Neutral

1-month return −3%

trailing

6-month return +25%

trailing

YTD return −9%

this year

Relative strength +11%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $8 › 200d $7 — 50d above 200d

Institutional flow Accumulating

+6% holders QoQ · +64 funds added

Insider flow Distributing

Net -$488.9K over 90 days · 100% sells

Short interest Falling

13.04% of float · ▼ -9.9% MoM · 5.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

352 holders — mid 3-yr range

Squeeze score 57

elevated · 0–100

Fundamentals

Excellent

Revenue growth +18%

Y/Y

Gross margin 12%

expanding

EPS growth +81%

Y/Y

Free cash flow $285.5M

Balance sheet $738.7M

net cash

Quant / Vol

risk profile

Very High

Volatility 64%

annualized · 1-yr

Max drawdown −53%

past year

ATR 5.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 7 of last 8

Latest guidance · from the 8-K filed Jul 29, 2026

Full Year 2026

Revenue Lowered $2.36B – $2.45B

Apr 29, 2026 $2.48B – $2.58B Jul 29, 2026 $2.36B – $2.45B

prior FY $2.53B midpoint −5.0% Y/Y

Adjusted EBITDA Non-GAAP Raised $271M – $303M

Apr 29, 2026 $267M – $306M Jul 29, 2026 $271M – $303M

Integrated Care Revenue growth percentage (year-over-year) Initiated 0.8% – 2.4%

Free Cash Flow Non-GAAP Maintained $130M – $170M

Apr 29, 2026 $130M – $170M Jul 29, 2026 $130M – $170M

Integrated Care Adjusted EBITDA margin Non-GAAP Raised 15.6% – 16.4%

Mar 31, 2026 15.1% – 16.1% Jul 29, 2026 15.6% – 16.4%

BetterHelp Adjusted EBITDA margin Non-GAAP Initiated 3% – 4.6%

3Q 2026

Revenue Initiated $569M – $609M

prior qtr $606.93M midpoint −3.0% QoQ

BetterHelp Adjusted EBITDA margin Non-GAAP Initiated 0.5% – 2.5%

Adjusted EBITDA Non-GAAP Initiated $62M – $74M

Prior guidance period ended · from the 8-K filed Apr 29, 2026

Revenue · 2Q 2026 $597M – $626M

Adjusted EBITDA · 2Q 2026 $55M – $67M

Guided vs delivered · last 8 settled

Revenue 2Q 2026

guided $597M – $626M

guided $597M – $626M $606.93M In line

Revenue Full Year 2025

guided $2.51B – $2.54B

guided $2.51B – $2.54B $2.53B In line

Revenue 4Q 2025

guided $622M – $652M

guided $622M – $652M $642.27M In line

Net loss per share Full Year 2025

guided $-1.35 – $-1.00

guided $-1.35 – $-1.00 $-1.14 In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−5% Bearish

Price vs 50-day avg

−20% Bearish

RSI (14)

37 Neutral

MACD trend

Positive Bullish

52-week position

36% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $8 › 200d $7 — 50d above 200d

Institutional flow Accumulating

+6% holders QoQ · +64 funds added

Insider flow Distributing

Net -$488.9K over 90 days · 100% sells

Short interest Falling

13.04% of float · ▼ -9.9% MoM · 5.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

352 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $4 Now $6 · 36% Range high $10

vs 200-day avg -5% vs 50-day avg -20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Average Monthly Revenue Per U.S. Integrated Care Member	$1.31	Three Months Ended June 30, 2026	—

BetterHelp Adjusted EBITDA non-GAAP	$2.36M	Six Months Ended June 30, 2026	—

BetterHelp Adjusted EBITDA margin % non-GAAP	0.5%	Six Months Ended June 30, 2026	—

BetterHelp Paying Users	0.35M	Average for Six Months Ended June 30, 2026	—

BetterHelp segment adjusted EBITDA margin non-GAAP	0.2%	Second Quarter 2026	—
Chronic Care Program Enrollment	1.27M	As of June 30, 2026	—
Consolidated Adjusted EBITDA non-GAAP	$123.88M	Six Months Ended June 30, 2026	—

Free Cash Flow non-GAAP	$9.44M	Six Months Ended June 30, 2026	—

Integrated Care Adjusted EBITDA non-GAAP	$121.52M	Six Months Ended June 30, 2026	—

Integrated Care Adjusted EBITDA margin % non-GAAP	15.4%	Six Months Ended June 30, 2026	—

Integrated Care segment adjusted EBITDA margin non-GAAP	16.5%	Second Quarter 2026	—
Total Visits	8.4M	Six Months Ended June 30, 2026	—

U.S. Integrated Care Members	100.3M	As of June 30, 2026	—
Capitalized expenditures and capitalized software development costs (Capex)	$127.5M	Full Year 2025	—
Cash flow from operations	$294.4M	Full Year 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Health Information Services — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TDOC Teladoc Health, Inc. this stock	$1.18B	-9.1%	+18.4%	—	13.0%
VEEV Veeva Systems Inc	$44.80B	+26.4%	+28.1%	45.3	3.6%
PMDIY Pro Medicus Ltd./ADR	$13.02B	-24.9%	—	—	0.0%
BTSG BrightSpring Health Services, Inc.	$12.25B	+62.6%	+28.2%	37.5	4.5%
TEM Tempus AI, Inc.	$11.56B	+19.7%	+83.4%	—	16.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

352

% held: 89.3%
Net QoQ: +10.1M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

258

View

Short & Settlement

Short Interest Falling

Shares short

23.7M

Days to cover: 5.0d
Change: -2.6M sh

View

Short Volume

Short vol %

48%

As of: Aug 28, 2026

Short Total

View

Fails to Deliver

FTD shares

158

Value: $1.0K
As of: Jul 31, 2026

View

Off-Exchange

Off-exchange %

38.5%

Week of: Jul 20, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$488.9K

Buyers / Sellers: 0 / 6

Buyers Sellers

View

Congressional Trades Sell

Member

Donald Sternoff Beyer

Amount: $1.0K–$15.0K
Traded: Nov 26, 2021

View

Financials

Revenue (FY)

$2.5B

Net income (FY): $-200.3M
EPS diluted: $-1.14

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 13, 2026
This year: 14

View

Proposed Sales

Value

$23.8K

Shares: 2.5K
Filed: Jul 6, 2026

View

Exempt Offerings

Offering

$834.0M

Filed: Jul 10, 2020

View

Earnings & Events

Earnings Calls

Last call

Jul 29, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
TDOC	-2.0%	-3.3%	+25.2%	-5.2%	-9.1%
SPY	+1.1%	+4.0%	+14.7%	+3.2%	+13.1%
vs SPY	-3.1%	-7.3%	+10.5%	-8.4%	-22.2%

TDOC · Teladoc Health, Inc.

Price & Indicators

Up next

AI Brief

Equibles Research

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance